This evidence gap reflects several factors including lack of pharmaceutical company funding (peptides not patentable, unprofitable versus proprietary drugs), regulatory challenges (FDA approval process expensive), and peptide use primarily occurring outside mainstream medicine in research chemical/biohacking communities
doi: 90
Regulatory restrictions make many of these compounds hard to obtain, particularly in the United States
At minimum: Outcomes Weight trend (weekly average) Waist circumference Body composition if available (DEXA, BIA with consistency) Strength markers (basic lifts, grip strength, functional tests) Safety Blood pressure + resting HR A1c and fasting glucose (more often if diabetes) CMP (liver/kidney) Lipids (periodic) If manipulating GH/IGF-1 signaling: IGF-1 (and clinical context matters) Stop criteria Persistent tachycardia, edema, severe fatigue, worsening glycemia, abnormal labs, or new symptoms you cant explain The what to ask your clinic questions (high signal, low fluff) If a clinic recommends a peptide stack, ask: What is the problem were solving, in one sentence
GLP-1, short for glucagon-like peptide-1, is one of the best-known incretin pathways involved in insulin-related signaling and appetite regulation
585 Compounds ALI6 ( 65 ) 586 and 66 587 can effectively block this interaction, which reverses the changes in cofilin signaling downstream of LilrB2 and the inhibition of neurite outgrowth, thus protecting neuronal cells from A toxicity
